Entrectinib has durable CNS activity in patients with NTRK fusion-positive tumours

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 25 / Springer Healthcare

Entrectinib has durable CNS activity in patients with NTRK fusion-positive tumours

Oncology Lung Cancer Solid Tumours ESMO-2020

Description

Thomas John discusses a pooled analysis of data from three early-phase trials showing the intracranial efficacy of entrectinib in patients with solid tumours and central nervous system metastases.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.